Chanice Henry | 10/30/2015
A new research report from Grand View Research inc, charts that the international epigenetics market is due to reach US$16.31 billion by 2022. The forecasted growth being fuelled by the increasing focus on cancer and other disease treatments with epigenetic modification bases.
The pharma industry is expected to be drawn towards collaboration to develop fresh therapeutic treatments with some drugs, with predicted commercialisation, already lining pipelines.
Products driving this trend...
To continue reading this story Click Here
RECOMMENDED
Upcoming Events
DigIT Pharma AI Commercial Excellence & Health 2025
September 01 - 03, 2025
Palace Hotel Berlin, Germany
Register Now |
View Agenda |
Learn More
AI for Pharma & Healthcare
23 - 25 September, 2025
Amsterdam
Register Now |
View Agenda |
Learn More